25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BX2 (BioXcel Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze BioXcel Therapeutics Inc together

I guess you are interested in BioXcel Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – BioXcel Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – BioXcel Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of BioXcel Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioXcel Therapeutics Inc

I send you an email if I find something interesting about BioXcel Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of BioXcel Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of BioXcel Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-26.68
Expected worth in 1 year
€-37.17
How sure are you?
18.2%

+ What do you gain per year?

Total Gains per Share
€-10.49
Return On Investment
-409.6%

For what price can you sell your share?

Current Price per Share
€2.56
Expected price per share
€2.56 - €2.56
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of BioXcel Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
€2.56
Intrinsic Value Per Share
€-259.76 - €-307.64
Total Value Per Share
€-286.44 - €-334.32

2.2. Growth of BioXcel Therapeutics Inc (5 min.)




Is BioXcel Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$93.1m-$9.5m-$71.7m-88.2%

How much money is BioXcel Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$14.8m-$44.7m$29.8m200.4%
Net Profit Margin-3,675.1%-14,515.9%--

How much money comes from the company's main activities?

2.3. Financial Health of BioXcel Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of BioXcel Therapeutics Inc?

Welcome investor! BioXcel Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of BioXcel Therapeutics Inc.

First you should know what it really means to hold a share of BioXcel Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of BioXcel Therapeutics Inc is €2.56. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BioXcel Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BioXcel Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-26.68. Based on the TTM, the Book Value Change Per Share is €-2.62 per quarter. Based on the YOY, the Book Value Change Per Share is €-4.65 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BioXcel Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-3.50-136.8%-4.80-187.6%-3.14-122.5%-3.14-122.6%-2.26-88.5%-2.21-86.4%
Usd Book Value Change Per Share-2.41-94.0%-2.95-115.2%-5.24-204.5%-3.16-123.5%-1.58-61.5%-1.36-53.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.41-94.0%-2.95-115.2%-5.24-204.5%-3.16-123.5%-1.58-61.5%-1.36-53.3%
Usd Price Per Share0.03-0.08-0.49-0.53-1.17-1.11-
Price to Earnings Ratio0.00-0.00--0.06--0.08--0.27--0.26-
Price-to-Total Gains Ratio-0.01--0.05--0.42--0.43--0.85--0.78-
Price to Book Ratio0.00-0.00-0.67-0.30-0.33-0.32-
Price-to-Total Gains Ratio-0.01--0.05--0.42--0.43--0.85--0.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.88
Number of shares347
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.95-1.58
Usd Total Gains Per Share-2.95-1.58
Gains per Quarter (347 shares)-1,023.43-546.57
Gains per Year (347 shares)-4,093.72-2,186.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4094-41040-2186-2196
20-8187-81980-4373-4382
30-12281-122920-6559-6568
40-16375-163860-8745-8754
50-20469-204800-10931-10940
60-24562-245740-13118-13126
70-28656-286680-15304-15312
80-32750-327620-17490-17498
90-36843-368560-19676-19684
100-40937-409500-21863-21870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%4.018.00.018.2%4.018.00.018.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%4.018.00.018.2%4.018.00.018.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BioXcel Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.140-2.622+22%-4.655+117%-2.810+31%-1.400-35%-1.213-43%
Book Value Per Share---26.680-23.313-13%-3.907-85%-7.587-72%-1.992-93%-1.303-95%
Current Ratio--1.6822.119-21%3.823-56%5.458-69%8.967-81%8.564-80%
Debt To Asset Ratio--3.4282.549+35%1.209+184%1.380+148%0.867+295%0.810+323%
Debt To Equity Ratio----0%6.322-100%2.375-100%1.471-100%1.365-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---116763544.746-124300926.641+6%-106690180.435-9%-94276560.104-19%-43652797.143-63%-39931247.170-66%
Eps---3.112-4.270+37%-2.787-10%-2.790-10%-2.013-35%-1.966-37%
Ev To Sales Ratio---89.725-86.131-4%-91.281+2%-97.925+9%-97.925+9%-97.925+9%
Free Cash Flow Per Share---4.244-5.160+22%-2.900-32%-3.045-28%-2.094-51%-2.094-51%
Free Cash Flow To Equity Per Share---3.018-2.534-16%-2.744-9%-1.687-44%-0.537-82%-0.537-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---307.637----------
Intrinsic Value_10Y_min---259.763----------
Intrinsic Value_1Y_max---14.899----------
Intrinsic Value_1Y_min---14.625----------
Intrinsic Value_3Y_max---56.904----------
Intrinsic Value_3Y_min---54.081----------
Intrinsic Value_5Y_max---113.546----------
Intrinsic Value_5Y_min---104.345----------
Market Cap7940633.600+99%72582.354230852.209-69%11666410.115-99%12457514.796-99%25820649.042-100%23984986.117-100%
Net Profit Margin---29.669-36.751+24%-145.159+389%-105.256+255%-63.154+113%-57.412+94%
Operating Margin----0%-62.1330%-62.9480%-37.7690%-34.3350%
Operating Ratio--31.85540.283-21%138.253-77%101.925-69%61.155-48%55.596-43%
Pb Ratio-0.096-10840%-0.001-0.003+292%0.673-100%0.304-100%0.332-100%0.322-100%
Pe Ratio-0.206-10840%-0.002-0.004+128%-0.063+3259%-0.081+4223%-0.271+14298%-0.263+13905%
Price Per Share2.560+99%0.0230.074-69%0.437-95%0.473-95%1.036-98%0.986-98%
Price To Free Cash Flow Ratio-0.151-10840%-0.001-0.004+157%-0.071+5069%-0.095+6778%-0.337+24340%-0.306+22118%
Price To Total Gains Ratio-1.196-10840%-0.011-0.047+332%-0.421+3752%-0.426+3798%-0.853+7700%-0.776+6999%
Quick Ratio--0.0060.012-51%0.011-46%0.008-28%0.005+19%0.004+31%
Return On Assets---0.283-0.254-10%-0.370+31%-0.269-5%-0.218-23%-0.217-23%
Return On Equity----0%-2.5310%-0.9630%-0.6420%-0.6100%
Total Gains Per Share---2.140-2.622+22%-4.655+117%-2.810+31%-1.400-35%-1.213-43%
Usd Book Value---93102163.763-81350516.869-13%-9561869.522-90%16533373.331-663%83670195.864-211%78850894.715-218%
Usd Book Value Change Per Share---2.408-2.949+22%-5.236+117%-3.161+31%-1.575-35%-1.364-43%
Usd Book Value Per Share---30.015-26.227-13%-4.396-85%-8.536-72%-2.241-93%-1.466-95%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---131358987.839-139838542.471+6%-120026452.990-9%-106061130.117-19%-49109396.786-63%-44922653.066-66%
Usd Eps---3.501-4.804+37%-3.136-10%-3.139-10%-2.264-35%-2.212-37%
Usd Free Cash Flow---14809185.113-18006975.084+22%-38756984.456+162%-30211460.972+104%-25590169.873+73%-23263790.794+57%
Usd Free Cash Flow Per Share---4.774-5.805+22%-3.262-32%-3.425-28%-2.356-51%-2.356-51%
Usd Free Cash Flow To Equity Per Share---3.396-2.851-16%-3.087-9%-1.898-44%-0.605-82%-0.605-82%
Usd Market Cap8933212.800+99%81655.148259708.735-69%13124711.379-99%14014704.146-99%29048230.172-100%26983109.381-100%
Usd Price Per Share2.880+99%0.0260.084-69%0.492-95%0.533-95%1.166-98%1.109-98%
Usd Profit---10859135.738-14899936.247+37%-44763809.541+312%-33701004.591+210%-29675720.942+173%-27763983.409+156%
Usd Revenue--366004.575566507.081-35%345004.313+6%335087.522+9%201052.513+82%182775.012+100%
Usd Total Gains Per Share---2.408-2.949+22%-5.236+117%-3.161+31%-1.575-35%-1.364-43%
 EOD+6 -2MRQTTM+16 -17YOY+15 -193Y+14 -205Y+11 -2310Y+11 -23

3.3 Fundamental Score

Let's check the fundamental score of BioXcel Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.206
Price to Book Ratio (EOD)Between0-1-0.096
Net Profit Margin (MRQ)Greater than0-29.669
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.006
Current Ratio (MRQ)Greater than11.682
Debt to Asset Ratio (MRQ)Less than13.428
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.283
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of BioXcel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5090.703
Ma 20Greater thanMa 502.560
Ma 50Greater thanMa 1002.284
Ma 100Greater thanMa 2001.339
OpenGreater thanClose2.560
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Fundamental data was last updated by Penke on 2025-05-01 22:55:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ BioXcel Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -2,966.9%Β means thatΒ €-29.67 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioXcel Therapeutics Inc:

  • The MRQ is -2,966.9%. The company is making a huge loss. -2
  • The TTM is -3,675.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,966.9%TTM-3,675.1%+708.2%
TTM-3,675.1%YOY-14,515.9%+10,840.8%
TTM-3,675.1%5Y-6,315.4%+2,640.3%
5Y-6,315.4%10Y-5,741.2%-574.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,966.9%-88.9%-2,878.0%
TTM-3,675.1%-182.1%-3,493.0%
YOY-14,515.9%-195.7%-14,320.2%
3Y-10,525.6%-244.6%-10,281.0%
5Y-6,315.4%-350.0%-5,965.4%
10Y-5,741.2%-491.0%-5,250.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ BioXcel Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • -28.3% Return on Assets means thatΒ BioXcel Therapeutics Inc generatedΒ €-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioXcel Therapeutics Inc:

  • The MRQ is -28.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.3%TTM-25.4%-3.0%
TTM-25.4%YOY-37.0%+11.6%
TTM-25.4%5Y-21.8%-3.6%
5Y-21.8%10Y-21.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.3%-11.3%-17.0%
TTM-25.4%-11.5%-13.9%
YOY-37.0%-11.5%-25.5%
3Y-26.9%-11.9%-15.0%
5Y-21.8%-12.5%-9.3%
10Y-21.7%-14.1%-7.6%
4.3.1.3. Return on Equity

Shows how efficient BioXcel Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means BioXcel Therapeutics Inc generated €0.00Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-253.1%+253.1%
TTM-5Y-64.2%+64.2%
5Y-64.2%10Y-61.0%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.5%+14.5%
TTM--15.1%+15.1%
YOY-253.1%-15.0%-238.1%
3Y-96.3%-17.5%-78.8%
5Y-64.2%-18.0%-46.2%
10Y-61.0%-19.9%-41.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BioXcel Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient BioXcel Therapeutics Inc is operatingΒ .

  • Measures how much profit BioXcel Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-6,213.3%+6,213.3%
TTM-5Y-3,776.9%+3,776.9%
5Y-3,776.9%10Y-3,433.5%-343.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--177.6%+177.6%
TTM--289.9%+289.9%
YOY-6,213.3%-208.5%-6,004.8%
3Y-6,294.8%-248.9%-6,045.9%
5Y-3,776.9%-360.9%-3,416.0%
10Y-3,433.5%-475.6%-2,957.9%
4.3.2.2. Operating Ratio

Measures how efficient BioXcel Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 31.86 means that the operating costs are €31.86 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 31.855. The company is inefficient in keeping operating costs low. -1
  • The TTM is 40.283. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ31.855TTM40.283-8.427
TTM40.283YOY138.253-97.970
TTM40.2835Y61.155-20.873
5Y61.15510Y55.596+5.560
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.8552.175+29.680
TTM40.2833.048+37.235
YOY138.2533.051+135.202
3Y101.9253.656+98.269
5Y61.1554.839+56.316
10Y55.5966.533+49.063
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BioXcel Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if BioXcel Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.68Β means the company has €1.68 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 1.682. The company is able to pay all its short-term debts. +1
  • The TTM is 2.119. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.682TTM2.119-0.437
TTM2.119YOY3.823-1.705
TTM2.1195Y8.967-6.848
5Y8.96710Y8.564+0.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6823.588-1.906
TTM2.1193.932-1.813
YOY3.8234.286-0.463
3Y5.4584.809+0.649
5Y8.9675.816+3.151
10Y8.5646.204+2.360
4.4.3.2. Quick Ratio

Measures if BioXcel Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.01Β means the company can pay off €0.01 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.006. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.012. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.006TTM0.012-0.006
TTM0.012YOY0.011+0.001
TTM0.0125Y0.005+0.007
5Y0.00510Y0.004+0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0062.845-2.839
TTM0.0123.439-3.427
YOY0.0114.128-4.117
3Y0.0084.673-4.665
5Y0.0055.938-5.933
10Y0.0046.556-6.552
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BioXcel Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of BioXcel Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ BioXcel Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.43Β means that BioXcel Therapeutics Inc assets areΒ financed with 342.8% credit (debt) and the remaining percentage (100% - 342.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 3.428. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.549. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.428TTM2.549+0.880
TTM2.549YOY1.209+1.340
TTM2.5495Y0.867+1.682
5Y0.86710Y0.810+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4280.342+3.086
TTM2.5490.342+2.207
YOY1.2090.330+0.879
3Y1.3800.329+1.051
5Y0.8670.359+0.508
10Y0.8100.382+0.428
4.5.4.2. Debt to Equity Ratio

Measures ifΒ BioXcel Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY6.322-6.322
TTM-5Y1.471-1.471
5Y1.47110Y1.365+0.105
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.410-0.410
TTM-0.427-0.427
YOY6.3220.408+5.914
3Y2.3750.428+1.947
5Y1.4710.447+1.024
10Y1.3650.494+0.871
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings BioXcel Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ BioXcel Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying €0.00Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.206. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.002. Based on the earnings, the company is expensive. -2
  • The TTM is -0.004. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.206MRQ-0.002-0.204
MRQ-0.002TTM-0.004+0.002
TTM-0.004YOY-0.063+0.059
TTM-0.0045Y-0.271+0.266
5Y-0.27110Y-0.263-0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.206-1.735+1.529
MRQ-0.002-2.410+2.408
TTM-0.004-3.010+3.006
YOY-0.063-3.337+3.274
3Y-0.081-4.007+3.926
5Y-0.271-6.317+6.046
10Y-0.263-6.805+6.542
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.151. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.004. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.151MRQ-0.001-0.149
MRQ-0.001TTM-0.004+0.002
TTM-0.004YOY-0.071+0.068
TTM-0.0045Y-0.337+0.333
5Y-0.33710Y-0.306-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.151-2.387+2.236
MRQ-0.001-3.244+3.243
TTM-0.004-3.963+3.959
YOY-0.071-4.345+4.274
3Y-0.095-5.424+5.329
5Y-0.337-8.416+8.079
10Y-0.306-9.392+9.086
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ BioXcel Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying €0.00Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.096. Based on the equity, the company is expensive. -2
  • The MRQ is -0.001. Based on the equity, the company is expensive. -2
  • The TTM is -0.003. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.096MRQ-0.001-0.095
MRQ-0.001TTM-0.003+0.003
TTM-0.003YOY0.673-0.676
TTM-0.0035Y0.332-0.335
5Y0.33210Y0.322+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0961.723-1.819
MRQ-0.0012.114-2.115
TTM-0.0032.377-2.380
YOY0.6732.474-1.801
3Y0.3042.757-2.453
5Y0.3323.696-3.364
10Y0.3224.294-3.972
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets38,338
Total Liabilities131,439
Total Stockholder Equity-93,101
 As reported
Total Liabilities 131,439
Total Stockholder Equity+ -93,101
Total Assets = 38,338

Assets

Total Assets38,338
Total Current Assets37,394
Long-term Assets944
Total Current Assets
Cash And Cash Equivalents 29,854
Net Receivables 131
Inventory 679
Other Current Assets 1,440
Total Current Assets  (as reported)37,394
Total Current Assets  (calculated)32,104
+/- 5,290
Long-term Assets
Property Plant Equipment 857
Long-term Assets Other 87
Long-term Assets  (as reported)944
Long-term Assets  (calculated)944
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities22,233
Long-term Liabilities109,206
Total Stockholder Equity-93,101
Total Current Liabilities
Accounts payable 15,990
Total Current Liabilities  (as reported)22,233
Total Current Liabilities  (calculated)15,990
+/- 6,243
Long-term Liabilities
Long term Debt 102,508
Capital Lease Obligations Min Short Term Debt439
Long-term Liabilities  (as reported)109,206
Long-term Liabilities  (calculated)102,947
+/- 6,259
Total Stockholder Equity
Total Stockholder Equity (as reported)-93,101
Total Stockholder Equity (calculated)0
+/- 93,101
Other
Capital Stock49
Common Stock Shares Outstanding 3,102
Net Debt 72,654
Net Invested Capital 9,407
Net Working Capital 15,161
Property Plant and Equipment Gross 2,359



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
43,697
36,392
85,812
70,462
238,749
219,936
200,389
281,107
261,332
239,439
211,045
248,235
244,818
205,853
180,103
140,097
100,449
73,702
82,323
65,435
48,892
38,338
38,33848,89265,43582,32373,702100,449140,097180,103205,853244,818248,235211,045239,439261,332281,107200,389219,936238,74970,46285,81236,39243,697
   > Total Current Assets 
41,361
34,107
83,598
68,313
236,133
217,065
196,783
276,658
256,929
236,812
207,562
244,924
241,661
202,868
177,268
138,235
98,738
72,143
80,917
64,181
47,792
37,394
37,39447,79264,18180,91772,14398,738138,235177,268202,868241,661244,924207,562236,812256,929276,658196,783217,065236,13368,31383,59834,10741,361
       Cash And Cash Equivalents 
40,252
32,426
80,079
65,495
233,428
213,119
194,015
273,057
252,912
232,968
200,435
233,452
232,314
193,725
165,521
127,545
89,961
65,221
74,141
56,271
40,387
29,854
29,85440,38756,27174,14165,22189,961127,545165,521193,725232,314233,452200,435232,968252,912273,057194,015213,119233,42865,49580,07932,42640,252
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
248
283
431
735
71
378
812
3
131
1313812378717354312832480000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
956
1,478
1,693
2,430
3,843
5,006
4,636
2,171
2,078
1,856
1,643
1,398
1,440
1,4401,3981,6431,8562,0782,1714,6365,0063,8432,4301,6931,478956000000000
   > Long-term Assets 
2,336
2,285
2,214
2,149
2,616
2,871
3,606
4,449
4,403
2,627
3,483
3,311
3,157
2,985
2,835
1,862
1,711
1,559
1,406
1,254
1,100
944
9441,1001,2541,4061,5591,7111,8622,8352,9853,1573,3113,4832,6274,4034,4493,6062,8712,6162,1492,2142,2852,336
       Property Plant Equipment 
2,285
2,234
2,163
2,098
2,530
2,784
2,973
2,819
2,648
2,541
2,518
2,386
2,232
2,060
1,910
1,775
1,624
1,472
1,319
1,167
1,013
857
8571,0131,1671,3191,4721,6241,7751,9102,0602,2322,3862,5182,5412,6482,8192,9732,7842,5302,0982,1632,2342,285
       Other Assets 
51
51
51
51
86
87
633
1,630
1,755
86
965
925
925
925
0
87
0
0
0
0
0
0
000000870925925925965861,7551,630633878651515151
> Total Liabilities 
9,277
9,497
13,226
17,068
17,811
13,240
13,652
13,696
15,776
17,772
17,025
83,973
117,832
129,078
127,098
134,233
141,057
130,210
154,686
139,736
134,525
131,439
131,439134,525139,736154,686130,210141,057134,233127,098129,078117,83283,97317,02517,77215,77613,69613,65213,24017,81117,06813,2269,4979,277
   > Total Current Liabilities 
8,206
8,468
12,265
16,161
16,344
11,842
12,324
12,441
14,596
16,667
15,997
19,995
23,378
32,898
28,759
34,744
39,408
27,267
31,481
27,288
25,557
22,233
22,23325,55727,28831,48127,26739,40834,74428,75932,89823,37819,99515,99716,66714,59612,44112,32411,84216,34416,16112,2658,4688,206
       Accounts payable 
4,238
4,953
6,733
10,434
8,557
3,979
5,310
2,497
3,439
4,678
5,065
6,021
5,872
10,228
7,742
11,203
10,669
13,654
17,220
13,256
14,889
15,990
15,99014,88913,25617,22013,65410,66911,2037,74210,2285,8726,0215,0654,6783,4392,4975,3103,9798,55710,4346,7334,9534,238
       Other Current Liabilities 
522
167
1,740
72
678
854
954
254
199
302
366
258
609
167
478
265
832
346
353
361
0
0
00361353346832265478167609258366302199254954854678721,740167522
   > Long-term Liabilities 
1,071
1,029
961
907
1,467
1,398
1,328
1,255
1,180
1,105
1,028
63,978
94,454
96,180
98,339
99,489
101,649
102,943
123,205
112,448
108,968
109,206
109,206108,968112,448123,205102,943101,64999,48998,33996,18094,45463,9781,0281,1051,1801,2551,3281,3981,4679079611,0291,071
       Capital Lease Obligations Min Short Term Debt
1,071
1,029
961
907
1,467
1,398
1,328
1,255
1,467
1,398
1,327
1,255
868
1,105
1,028
949
529
440
350
256
529
439
4395292563504405299491,0281,1058681,2551,3271,3981,4671,2551,3281,3981,4679079611,0291,071
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
1,954
1,891
2,343
0
2,026
0
0
0
0
0
0
0000002,02602,3431,8911,95400000000000
> Total Stockholder Equity
34,420
26,895
72,586
53,394
220,938
206,696
186,737
267,411
245,556
221,667
194,020
164,262
126,986
76,775
53,005
5,864
-40,608
-56,508
-72,363
-74,301
-85,633
-93,101
-93,101-85,633-74,301-72,363-56,508-40,6085,86453,00576,775126,986164,262194,020221,667245,556267,411186,737206,696220,93853,39472,58626,89534,420
   Common Stock
18
18
20
20
24
24
25
28
28
28
28
28
28
28
0
29
0
0
0
0
0
0
0000002902828282828282825242420201818
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 0000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,266
Cost of Revenue-2,143
Gross Profit123123
 
Operating Income (+$)
Gross Profit123
Operating Expense-67,070
Operating Income-64,804-66,947
 
Operating Expense (+$)
Research Development30,435
Selling General Administrative34,492
Selling And Marketing Expenses-
Operating Expense67,07064,927
 
Net Interest Income (+$)
Interest Income2,602
Interest Expense-15,129
Other Finance Cost-0
Net Interest Income-12,527
 
Pretax Income (+$)
Operating Income-64,804
Net Interest Income-12,527
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-59,599-82,536
EBIT - interestExpense = -15,129
-59,599
-44,470
Interest Expense15,129
Earnings Before Interest and Taxes (EBIT)--44,470
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-59,599
Tax Provision--
Net Income From Continuing Ops-59,599-59,599
Net Income-59,599
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net17,73212,527
 

Technical Analysis of BioXcel Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BioXcel Therapeutics Inc. The general trend of BioXcel Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BioXcel Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. BioXcel Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioXcel Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.56 < 2.56 < 2.56.

The bearish price targets are: 2.56 > 2.56 > 2.56.

Know someone who trades $BX2? Share this with them.πŸ‘‡

BioXcel Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioXcel Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioXcel Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioXcel Therapeutics Inc. The current macd is 0.07431807.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BioXcel Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for BioXcel Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the BioXcel Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioXcel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioXcel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioXcel Therapeutics Inc. The current adx is 80.78.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy BioXcel Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
BioXcel Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioXcel Therapeutics Inc. The current sar is 1.5326784.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
BioXcel Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioXcel Therapeutics Inc. The current rsi is 90.70. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
BioXcel Therapeutics Inc Daily Relative Strength Index (RSI) ChartBioXcel Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioXcel Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BioXcel Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
BioXcel Therapeutics Inc Daily Stochastic Oscillator ChartBioXcel Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioXcel Therapeutics Inc. The current cci is -66.66666667.

BioXcel Therapeutics Inc Daily Commodity Channel Index (CCI) ChartBioXcel Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioXcel Therapeutics Inc. The current cmo is 86.33.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioXcel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartBioXcel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioXcel Therapeutics Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
BioXcel Therapeutics Inc Daily Williams %R ChartBioXcel Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioXcel Therapeutics Inc. The current atr is 0.00837559.

BioXcel Therapeutics Inc Daily Average True Range (ATR) ChartBioXcel Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioXcel Therapeutics Inc. The current obv is 208,495.

BioXcel Therapeutics Inc Daily On-Balance Volume (OBV) ChartBioXcel Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioXcel Therapeutics Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BioXcel Therapeutics Inc Daily Money Flow Index (MFI) ChartBioXcel Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioXcel Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-20 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-12 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-20 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-03 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-06 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-09 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-15 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-16 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-29 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-31 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-10 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

BioXcel Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioXcel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5090.703
Ma 20Greater thanMa 502.560
Ma 50Greater thanMa 1002.284
Ma 100Greater thanMa 2001.339
OpenGreater thanClose2.560
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of BioXcel Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on BioXcel Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BioXcel Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioXcel Therapeutics Inc

I send you an email if I find something interesting about BioXcel Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about BioXcel Therapeutics Inc.

Receive notifications about BioXcel Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.